These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2045 related items for PubMed ID: 16285075

  • 21. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 22. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 23. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Vachiéry JL.
    Rev Med Brux; 2003 Sep; 24(4):A249-52. PubMed ID: 14606288
    [Abstract] [Full Text] [Related]

  • 24. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 25. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Aug; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 26. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 08; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 28. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract] [Full Text] [Related]

  • 29. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators.
    N Engl J Med; 2003 Nov 13; 349(20):1893-906. PubMed ID: 14610160
    [Abstract] [Full Text] [Related]

  • 30. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 13; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 31. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
    Kageyama S.
    Nihon Yakurigaku Zasshi; 2008 Mar 13; 131(3):180-1. PubMed ID: 18421844
    [No Abstract] [Full Text] [Related]

  • 32. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov 13; 45():2626-8, 2630-3. PubMed ID: 10587770
    [Abstract] [Full Text] [Related]

  • 33. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Nov 13; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 34. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun 13; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 35. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 13; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 36. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
    Mazzotta G, Vecchio C.
    G Ital Cardiol; 1994 Jan 13; 24(1):59-70. PubMed ID: 8200499
    [Abstract] [Full Text] [Related]

  • 37. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 38. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
    Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA.
    N Engl J Med; 2004 Sep 23; 351(13):1285-95. PubMed ID: 15385655
    [Abstract] [Full Text] [Related]

  • 39. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct 23; 145(43):51. PubMed ID: 14664222
    [No Abstract] [Full Text] [Related]

  • 40. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB.
    Cardiol Clin; 1995 Aug 23; 13(3):379-90. PubMed ID: 7585774
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 103.